These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 10628898)

  • 1. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
    He G; Massarella J; Ward P
    Clin Pharmacokinet; 1999 Dec; 37(6):471-84. PubMed ID: 10628898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
    Hill G; Cihlar T; Oo C; Ho ES; Prior K; Wiltshire H; Barrett J; Liu B; Ward P
    Drug Metab Dispos; 2002 Jan; 30(1):13-9. PubMed ID: 11744606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
    Oo C; Barrett J; Hill G; Mann J; Dorr A; Dutkowski R; Ward P
    Paediatr Drugs; 2001; 3(3):229-36. PubMed ID: 11310719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
    Snell P; Oo C; Dorr A; Barrett J
    Br J Clin Pharmacol; 2002 Oct; 54(4):372-7. PubMed ID: 12392584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.
    Massarella JW; He GZ; Dorr A; Nieforth K; Ward P; Brown A
    J Clin Pharmacol; 2000 Aug; 40(8):836-43. PubMed ID: 10934667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oseltamivir: a clinical and pharmacological perspective.
    Doucette KE; Aoki FY
    Expert Opin Pharmacother; 2001 Oct; 2(10):1671-83. PubMed ID: 11825310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.
    Sweeny DJ; Lynch G; Bidgood AM; Lew W; Wang KY; Cundy KC
    Drug Metab Dispos; 2000 Jul; 28(7):737-41. PubMed ID: 10859145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
    Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T
    Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H; Jeffery J; Sitar DS; Aoki FY
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
    Davies BE
    J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii5-ii10. PubMed ID: 20215135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
    Oo C; Hill G; Dorr A; Liu B; Boellner S; Ward P
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):411-5. PubMed ID: 12910331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.
    Chairat K; Tarning J; White NJ; Lindegardh N
    J Clin Pharmacol; 2013 Feb; 53(2):119-39. PubMed ID: 23436258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.
    Eisenberg EJ; Bidgood A; Cundy KC
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1949-52. PubMed ID: 9303391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuraminidase inhibitors: zanamivir and oseltamivir.
    McNicholl IR; McNicholl JJ
    Ann Pharmacother; 2001 Jan; 35(1):57-70. PubMed ID: 11197587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.
    Ito M; Kusuhara H; Ose A; Kondo T; Tanabe K; Nakayama H; Horita S; Fujita T; Sugiyama Y
    AAPS J; 2017 Jan; 19(1):286-297. PubMed ID: 27800573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oseltamivir.
    Bardsley-Elliot A; Noble S
    Drugs; 1999 Nov; 58(5):851-60; discussion 861-2. PubMed ID: 10595865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.
    Li W; Escarpe PA; Eisenberg EJ; Cundy KC; Sweet C; Jakeman KJ; Merson J; Lew W; Williams M; Zhang L; Kim CU; Bischofberger N; Chen MS; Mendel DB
    Antimicrob Agents Chemother; 1998 Mar; 42(3):647-53. PubMed ID: 9517946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
    Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
    Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
    Parrott N; Davies B; Hoffmann G; Koerner A; Lave T; Prinssen E; Theogaraj E; Singer T
    Clin Pharmacokinet; 2011 Sep; 50(9):613-23. PubMed ID: 21827216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.
    Ariano RE; Sitar DS; Zelenitsky SA; Zarychanski R; Pisipati A; Ahern S; Kanji S; Rello J; Kumar A
    CMAJ; 2010 Mar; 182(4):357-63. PubMed ID: 20159892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.